July 27, 2017
Cambridge, Ma

Publication: Gene Transfer Corrects Severe Muscle Defects in Mice with Duchenne Muscular Dystrophy

Results from a study led by Dr. Dongsheng Duan of the University of Missouri showed that AAV-mediated microdystrophin gene transfer effectively restored muscle strength in a severe mouse model of Duchenne muscular dystrophy (DMD). These findings further support the initiation of clinical trials for SGT-001. 

Read the full publication here.

Related news


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.


Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”


More information about Solid?

Please subscribe to receive our latest news